Brief: Cellceutix to submit special protocol assessment request to FDA for Phase 3 clinical study of antibiotic Brilacidin for absssi
09/02/2016 14:25
Feb 9 (Reuters) - Cellceutix Corp CTIX.PK : * To submit special protocol assessment request to FDA for Phase 3 clinical study of antibiotic Brilacidin for ABSSSI * Source text for Eikon urn:newsml:reuters.com:*:nMKWJxcvca * Further company coverage CTIX.PK ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review